Larimar Therapeutics, Inc. (LRMR): R&D Expense
$154.22M
Year ended 2025-12-31
$157.34M
Trailing 12 months to 2026-06-30
+85.3%
3-year compound annual growth
+37.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $154.22M | +110.5% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $73.28M | +164.8% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $27.67M | +14.1% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $24.25M | -36.8% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $38.40M | +22.3% | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $31.41M | +51.1% | 2022-03-25, From 2020-01-01 |
| 2019-12-31 | $20.79M | n/c | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $47.93M | +17.4% | 2020-03-05, From 2018-01-01 |
| 2017-12-31 | $40.84M | +2.3% | 2020-03-05, From 2017-01-01 |
| 2016-12-31 | $39.94M | -26.9% | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | $54.62M | +99.4% | 2018-03-09, From 2015-01-01 |
| 2014-12-31 | $27.39M | +186.5% | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | $9.56M | -17.2% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $11.54M | n/a | 2015-03-25, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $154.22M | +110.5% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $47.39M | +25.5% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $90.96M | +78.3% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $25.58M | -30.4% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $9.90M | -23.8% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| Veradermics, Inc (MANE) | 2025-12-31 | $62.06M | +166.6% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $5.74M | -27.9% |
Compare LRMR, XBIT, PRLD, WHWK side by side · Screen every company in Pharmaceutical Preparations ↗